India restricts cough-and-cold drug combinations for children under four
The government has restricted the manufacture, sale and distribution of fixed-dose combinations containing chlorpheniramine maleate and phenylephrine hydrochloride, requiring labels to state they must not be used in children below four years.
What happened
retail-company · India has restricted manufacture, sale and distribution of all chlorpheniramine maleate and phenylephrine hydrochloride fixed-dose
Key facts
- Children below 4 years
- Section 26A
- Drugs and Cosmetics Act, 1940
Why this matters
Assess acquisition or partnership targets with compliant pediatric OTC formulations and regulatory capabilities as affected fixed-dose combination products face reduced market access.
What to watch
- Gazette notification effective date, implementation guidance, and any grace period for existing inventory.
- State drug-controller inspection activity, notices, seizures, or penalties involving affected combination products.
- Manufacturer announcements of pack redesigns, SKU discontinuations, reformulations, recalls, or distributor-return programs.
- Changes in sales mix for pediatric cough-and-cold products versus single-ingredient and non-drug alternatives.
- E-pharmacy platform restrictions, prescription requirements, age-verification prompts, or product delistings.
- Further pediatric restrictions on other fixed-dose cough-and-cold combinations or broader labeling mandates.
- Map all SKUs containing chlorpheniramine maleate plus phenylephrine hydrochloride, including private-label, regional-brand, and distributor-held inventory.
- Update POS, e-pharmacy, and pharmacist decision-support systems to flag the under-four restriction and prevent inappropriate recommendation or fulfillment.
- Obtain manufacturer confirmation on revised labeling, effective dates, replacement stock, return policies, and credit terms for noncompliant packs.
- Train pharmacy staff to ask for child age when cough-and-cold products are requested and to recommend compliant alternatives or physician consultation.
- Audit shelf tags, online product descriptions, marketplace listings, and delivery-pharmacist scripts for mandated warning visibility.
- Increase availability of compliant pediatric alternatives, especially saline, fever-management, and non-pharmacological cold-care products, while avoiding unsupported therapeutic substitution claims.